» Articles » PMID: 20042635

ALK5 Phosphorylation of the Endoglin Cytoplasmic Domain Regulates Smad1/5/8 Signaling and Endothelial Cell Migration

Overview
Journal Carcinogenesis
Specialty Oncology
Date 2010 Jan 1
PMID 20042635
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Endoglin, an endothelial cell-specific transforming growth factor-beta (TGF-beta) superfamily coreceptor, has an essential role in angiogenesis. Endoglin-null mice have an embryonic lethal phenotype due to defects in angiogenesis and mutations in endoglin result in the vascular disease hereditary hemorrhagic telangiectasia type I. Increased endoglin expression in the proliferating endothelium of tumors has been correlated with metastasis, tumor grade and decreased survival. Although endoglin is thought to regulate TGF-beta superfamily signaling in endothelial cells through regulating the balance between two TGF-beta-responsive pathways, the activin receptor-like kinase 5 (ALK5)/Smad2/3 pathway and the activin receptor-like kinase 1 (ALK1)/Smad1/5/8 pathway, the mechanism by which endoglin regulates angiogenesis has not been defined. Here, we investigate the role of the cytoplasmic domain of endoglin and its phosphorylation by ALK5 in regulating endoglin function in endothelial cells. We demonstrate that the cytoplasmic domain of endoglin is basally phosphorylated by ALK5, primarily on serines 646 and 649, in endothelial cells. Functionally, the loss of phosphorylation at serine 646 resulted in a loss of endoglin-mediated inhibition of Smad1/5/8 signaling in response to TGF-beta and endothelial cell migration, whereas loss of phosphorylation at both serines 646 and 649 resulted in a loss of endoglin-mediated inhibition of Smad1/5/8 signaling in response to bone morphogenetic protein-9. Taken together, these results support endoglin phosphorylation by ALK5 as an important mechanism for regulating TGF-beta superfamily signaling and migration in endothelial cells.

Citing Articles

Activins and Inhibins in Cardiovascular Pathophysiology.

Tang W, Gu Z, Guo J, Lin M, Tao H, Jia D Biomolecules. 2024; 14(11).

PMID: 39595638 PMC: 11592067. DOI: 10.3390/biom14111462.


Harnessing synergistic effects of MMP-2 Inhibition and bFGF to simultaneously preserve and vascularize cardiac extracellular matrix after myocardial infarction.

Niu H, Liu Z, Guan Y, Wen J, Dang Y, Guan J Acta Biomater. 2024; 191:189-204.

PMID: 39532649 PMC: 11659021. DOI: 10.1016/j.actbio.2024.10.050.


Transforming growth factor-β in tumour development.

Trelford C, Dagnino L, Di Guglielmo G Front Mol Biosci. 2022; 9:991612.

PMID: 36267157 PMC: 9577372. DOI: 10.3389/fmolb.2022.991612.


The role of endoglin and its soluble form in pathogenesis of preeclampsia.

Margioula-Siarkou G, Margioula-Siarkou C, Petousis S, Margaritis K, Vavoulidis E, Gullo G Mol Cell Biochem. 2021; 477(2):479-491.

PMID: 34783962 DOI: 10.1007/s11010-021-04294-z.


High-throughput measurements of bone morphogenetic protein/bone morphogenetic protein receptor interactions using biolayer interferometry.

Khodr V, Machillot P, Migliorini E, Reiser J, Picart C Biointerphases. 2021; 16(3):031001.

PMID: 34241280 PMC: 7614001. DOI: 10.1116/6.0000926.


References
1.
Attisano L, Carcamo J, Ventura F, Weis F, Massague J, Wrana J . Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell. 1993; 75(4):671-80. DOI: 10.1016/0092-8674(93)90488-c. View

2.
Lee N, Ray B, How T, Blobe G . Endoglin promotes transforming growth factor beta-mediated Smad 1/5/8 signaling and inhibits endothelial cell migration through its association with GIPC. J Biol Chem. 2008; 283(47):32527-33. PMC: 2583306. DOI: 10.1074/jbc.M803059200. View

3.
Pece-Barbara N, Vera S, Kathirkamathamby K, Liebner S, Di Guglielmo G, Dejana E . Endoglin null endothelial cells proliferate faster and are more responsive to transforming growth factor beta1 with higher affinity receptors and an activated Alk1 pathway. J Biol Chem. 2005; 280(30):27800-8. DOI: 10.1074/jbc.M503471200. View

4.
Saad R, Liu Y, Nathan G, Celebrezze J, Medich D, Silverman J . Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol. 2003; 17(2):197-203. DOI: 10.1038/modpathol.3800034. View

5.
Yang L, Lu W, Huang G, Wang W . Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma. BMC Cancer. 2006; 6:110. PMC: 1475877. DOI: 10.1186/1471-2407-6-110. View